APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-23 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Industry Research

IL-23 Receptor Antagonist Industry Research Report 2026

27 December 2025135 pages

Choose your research edition.

Industry ResearchIL-23 Receptor Antagonist Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-23 Receptor Antagonist Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal IL-23 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-23 Receptor Antagonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-23 Receptor Antagonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global IL-23 Receptor Antagonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for IL-23 Receptor Antagonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for IL-23 Receptor Antagonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of IL-23 Receptor Antagonist include Qyuns Therapeutics, China Medical System, Huadong Medicine, Bio-Thera Solutions, Teva, Sun Pharma, Sandoz, Samsung Bioepis and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global IL-23 Receptor Antagonist market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

IL-23 Receptor Antagonist Market by Company

Qyuns Therapeutics

China Medical System

Huadong Medicine

Bio-Thera Solutions

Teva

Sun Pharma

Sandoz

Samsung Bioepis

Janssen Pharmaceuticals

Eli Lilly

Celltrion

Biocon Biologics

Amgen

Almirall

AbbVie Biotechnology

IL-23 Receptor Antagonist Segment by Type

Briakinumab

Guselkumab

Mirikizumab

Risankizumab

Tildrakizumab

Ustekinumab

Other

IL-23 Receptor Antagonist Segment by Application

Plaque Psoriasis

Crohn's Disease

Psoriatic Arthritis

Other

IL-23 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-23 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of IL-23 Receptor Antagonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of IL-23 Receptor Antagonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of IL-23 Receptor Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global IL-23 Receptor Antagonist Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global IL-23 Receptor Antagonist Sales (K Units) of Manufacturers (2021-2026) Table 7. Global IL-23 Receptor Antagonist Sales Market Share by Manufacturers (2021-2026) Table 8. Global IL-23 Receptor Antagonist Revenue of Manufacturers (2021-2026) Table 9. Global IL-23 Receptor Antagonist Revenue Share by Manufacturers (2021-2026) Table 10. Global Market IL-23 Receptor Antagonist Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global IL-23 Receptor Antagonist Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of IL-23 Receptor Antagonist, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of IL-23 Receptor Antagonist, Product Type & Application Table 14. Global IL-23 Receptor Antagonist Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global IL-23 Receptor Antagonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Qyuns Therapeutics Company Information Table 19. Qyuns Therapeutics Business Overview Table 20. Qyuns Therapeutics IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio Table 22. Qyuns Therapeutics Recent Developments Table 23. China Medical System Company Information Table 24. China Medical System Business Overview Table 25. China Medical System IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. China Medical System IL-23 Receptor Antagonist Product Portfolio Table 27. China Medical System Recent Developments Table 28. Huadong Medicine Company Information Table 29. Huadong Medicine Business Overview Table 30. Huadong Medicine IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Huadong Medicine IL-23 Receptor Antagonist Product Portfolio Table 32. Huadong Medicine Recent Developments Table 33. Bio-Thera Solutions Company Information Table 34. Bio-Thera Solutions Business Overview Table 35. Bio-Thera Solutions IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio Table 37. Bio-Thera Solutions Recent Developments Table 38. Teva Company Information Table 39. Teva Business Overview Table 40. Teva IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Teva IL-23 Receptor Antagonist Product Portfolio Table 42. Teva Recent Developments Table 43. Sun Pharma Company Information Table 44. Sun Pharma Business Overview Table 45. Sun Pharma IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Sun Pharma IL-23 Receptor Antagonist Product Portfolio Table 47. Sun Pharma Recent Developments Table 48. Sandoz Company Information Table 49. Sandoz Business Overview Table 50. Sandoz IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sandoz IL-23 Receptor Antagonist Product Portfolio Table 52. Sandoz Recent Developments Table 53. Samsung Bioepis Company Information Table 54. Samsung Bioepis Business Overview Table 55. Samsung Bioepis IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio Table 57. Samsung Bioepis Recent Developments Table 58. Janssen Pharmaceuticals Company Information Table 59. Janssen Pharmaceuticals Business Overview Table 60. Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio Table 62. Janssen Pharmaceuticals Recent Developments Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Eli Lilly IL-23 Receptor Antagonist Product Portfolio Table 67. Eli Lilly Recent Developments Table 68. Celltrion Company Information Table 69. Celltrion Business Overview Table 70. Celltrion IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Celltrion IL-23 Receptor Antagonist Product Portfolio Table 72. Celltrion Recent Developments Table 73. Biocon Biologics Company Information Table 74. Biocon Biologics Business Overview Table 75. Biocon Biologics IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Biocon Biologics IL-23 Receptor Antagonist Product Portfolio Table 77. Biocon Biologics Recent Developments Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Amgen IL-23 Receptor Antagonist Product Portfolio Table 82. Amgen Recent Developments Table 83. Almirall Company Information Table 84. Almirall Business Overview Table 85. Almirall IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Almirall IL-23 Receptor Antagonist Product Portfolio Table 87. Almirall Recent Developments Table 88. AbbVie Biotechnology Company Information Table 89. AbbVie Biotechnology Business Overview Table 90. AbbVie Biotechnology IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio Table 92. AbbVie Biotechnology Recent Developments Table 93. Global IL-23 Receptor Antagonist Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global IL-23 Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 95. Global IL-23 Receptor Antagonist Sales Market Share by Region (2021-2026) Table 96. Global IL-23 Receptor Antagonist Sales by Region (2027-2032) & (K Units) Table 97. Global IL-23 Receptor Antagonist Sales Market Share by Region (2027-2032) Table 98. Global IL-23 Receptor Antagonist Revenue by Region (2021-2026) & (US$ Million) Table 99. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2021-2026) Table 100. Global IL-23 Receptor Antagonist Revenue by Region (2027-2032) & (US$ Million) Table 101. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2027-2032) Table 102. North America IL-23 Receptor Antagonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 104. North America IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 105. North America IL-23 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 106. North America IL-23 Receptor Antagonist Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe IL-23 Receptor Antagonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 109. Europe IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 110. Europe IL-23 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe IL-23 Receptor Antagonist Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific IL-23 Receptor Antagonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific IL-23 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific IL-23 Receptor Antagonist Revenue by Country (2027-2032) & (US$ Million) Table 117. South America IL-23 Receptor Antagonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 119. South America IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 120. South America IL-23 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 121. South America IL-23 Receptor Antagonist Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa IL-23 Receptor Antagonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa IL-23 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa IL-23 Receptor Antagonist Revenue by Country (2027-2032) & (US$ Million) Table 127. Global IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 128. Global IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 129. Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2026) Table 130. Global IL-23 Receptor Antagonist Sales Market Share by Type (2027-2032) Table 131. Global IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 132. Global IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 133. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2026) Table 134. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2027-2032) Table 135. Global IL-23 Receptor Antagonist Price by Type (2021-2026) & (US$/Unit) Table 136. Global IL-23 Receptor Antagonist Price by Type (2027-2032) & (US$/Unit) Table 137. Global IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 138. Global IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 139. Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2026) Table 140. Global IL-23 Receptor Antagonist Sales Market Share by Application (2027-2032) Table 141. Global IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 142. Global IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 143. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2026) Table 144. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2027-2032) Table 145. Global IL-23 Receptor Antagonist Price by Application (2021-2026) & (US$/Unit) Table 146. Global IL-23 Receptor Antagonist Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. IL-23 Receptor Antagonist Distributors List Table 150. IL-23 Receptor Antagonist Customers List Table 151. IL-23 Receptor Antagonist Industry Trends Table 152. IL-23 Receptor Antagonist Industry Drivers Table 153. IL-23 Receptor Antagonist Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. IL-23 Receptor Antagonist Product Image Figure 5. Global IL-23 Receptor Antagonist Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global IL-23 Receptor Antagonist Market Size (2021-2032) & (US$ Million) Figure 7. Global IL-23 Receptor Antagonist Sales (2021-2032) & (K Units) Figure 8. Global IL-23 Receptor Antagonist Average Price (US$/Unit) & (2021-2032) Figure 9. Briakinumab Product Image Figure 10. Guselkumab Product Image Figure 11. Mirikizumab Product Image Figure 12. Risankizumab Product Image Figure 13. Tildrakizumab Product Image Figure 14. Ustekinumab Product Image Figure 15. Other Product Image Figure 16. Plaque Psoriasis Product Image Figure 17. Crohn's Disease Product Image Figure 18. Psoriatic Arthritis Product Image Figure 19. Other Product Image Figure 20. Global IL-23 Receptor Antagonist Revenue Share by Manufacturers in 2025 Figure 21. Global Manufacturers of IL-23 Receptor Antagonist, Manufacturing Sites & Headquarters Figure 22. Global Top 5 and 10 IL-23 Receptor Antagonist Players Market Share by Revenue in 2025 Figure 23. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global IL-23 Receptor Antagonist Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 25. Global IL-23 Receptor Antagonist Sales by Region in 2025 Figure 26. Global IL-23 Receptor Antagonist Revenue by Region in 2025 Figure 27. North America IL-23 Receptor Antagonist Market Size by Country in 2025 Figure 28. North America IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 29. North America IL-23 Receptor Antagonist Revenue Market Share by Country (2021-2032) Figure 30. United States IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Canada IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Mexico IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Europe IL-23 Receptor Antagonist Market Size by Country in 2025 Figure 34. Europe IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 35. Europe IL-23 Receptor Antagonist Revenue Market Share by Country (2021-2032) Figure 36. Germany IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. France IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. U.K. IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Italy IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Russia IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Spain IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Netherlands IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Switzerland IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Sweden IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Poland IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Asia Pacific IL-23 Receptor Antagonist Market Size by Country in 2025 Figure 47. Asia Pacific IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 48. Asia Pacific IL-23 Receptor Antagonist Revenue Market Share by Country (2021-2032) Figure 49. China IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Japan IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South Korea IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. India IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Australia IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Taiwan IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. South America IL-23 Receptor Antagonist Market Size by Country in 2025 Figure 58. South America IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 59. South America IL-23 Receptor Antagonist Revenue Market Share by Country (2021-2032) Figure 60. Brazil IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Argentina IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Chile IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa IL-23 Receptor Antagonist Market Size by Country in 2025 Figure 64. Middle East and Africa IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa IL-23 Receptor Antagonist Revenue Market Share by Country (2021-2032) Figure 66. Egypt IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries IL-23 Receptor Antagonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2032) Figure 72. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2032) Figure 73. Global IL-23 Receptor Antagonist Price (US$/Unit) by Type (2021-2032) Figure 74. Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2032) Figure 75. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2032) Figure 76. Global IL-23 Receptor Antagonist Price (US$/Unit) by Application (2021-2032) Figure 77. IL-23 Receptor Antagonist Value Chain Figure 78. IL-23 Receptor Antagonist Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. IL-23 Receptor Antagonist Industry Opportunities and Challenges

Scope & coverage.

Types
  • Briakinumab
  • Guselkumab
  • Mirikizumab
  • Risankizumab
  • Tildrakizumab
  • Ustekinumab
  • Other
Applications
  • Plaque Psoriasis
  • Crohn's Disease
  • Psoriatic Arthritis
  • Other
Companies covered
  • Qyuns Therapeutics
  • China Medical System
  • Huadong Medicine
  • Bio-Thera Solutions
  • Teva
  • Sun Pharma
  • Sandoz
  • Samsung Bioepis
  • Janssen Pharmaceuticals
  • Eli Lilly
  • Celltrion
  • Biocon Biologics
  • Amgen
  • Almirall
  • AbbVie Biotechnology

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global IL-23 Receptor Antagonist Market Size (2021-2032)
  4. 2.2.2 Global IL-23 Receptor Antagonist Sales (2021-2032)
  5. 2.2.3 Global IL-23 Receptor Antagonist Market Average Price (2021-2032)
  6. 2.3 IL-23 Receptor Antagonist by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Briakinumab
  9. 2.3.3 Guselkumab
  10. 2.3.4 Mirikizumab
  11. 2.3.5 Risankizumab
  12. 2.3.6 Tildrakizumab
  13. 2.3.7 Ustekinumab
  14. 2.3.8 Other
  15. 2.4 IL-23 Receptor Antagonist by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Plaque Psoriasis
  18. 2.4.3 Crohn's Disease
  19. 2.4.4 Psoriatic Arthritis
  20. 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global IL-23 Receptor Antagonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global IL-23 Receptor Antagonist Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global IL-23 Receptor Antagonist Revenue of Manufacturers (2021-2026)
  4. 3.4 Global IL-23 Receptor Antagonist Average Price by Manufacturers (2021-2026)
  5. 3.5 Global IL-23 Receptor Antagonist Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of IL-23 Receptor Antagonist, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of IL-23 Receptor Antagonist, Product Type & Application
  8. 3.8 Global Manufacturers of IL-23 Receptor Antagonist, Established Date
  9. 3.9 Global IL-23 Receptor Antagonist Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Qyuns Therapeutics
  2. 4.1.1 Qyuns Therapeutics Company Information
  3. 4.1.2 Qyuns Therapeutics Business Overview
  4. 4.1.3 Qyuns Therapeutics IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio
  6. 4.1.5 Qyuns Therapeutics Recent Developments
  7. 4.2 China Medical System
  8. 4.2.1 China Medical System Company Information
  9. 4.2.2 China Medical System Business Overview
  10. 4.2.3 China Medical System IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 China Medical System IL-23 Receptor Antagonist Product Portfolio
  12. 4.2.5 China Medical System Recent Developments
  13. 4.3 Huadong Medicine
  14. 4.3.1 Huadong Medicine Company Information
  15. 4.3.2 Huadong Medicine Business Overview
  16. 4.3.3 Huadong Medicine IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Huadong Medicine IL-23 Receptor Antagonist Product Portfolio
  18. 4.3.5 Huadong Medicine Recent Developments
  19. 4.4 Bio-Thera Solutions
  20. 4.4.1 Bio-Thera Solutions Company Information
  21. 4.4.2 Bio-Thera Solutions Business Overview
  22. 4.4.3 Bio-Thera Solutions IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio
  24. 4.4.5 Bio-Thera Solutions Recent Developments
  25. 4.5 Teva
  26. 4.5.1 Teva Company Information
  27. 4.5.2 Teva Business Overview
  28. 4.5.3 Teva IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Teva IL-23 Receptor Antagonist Product Portfolio
  30. 4.5.5 Teva Recent Developments
  31. 4.6 Sun Pharma
  32. 4.6.1 Sun Pharma Company Information
  33. 4.6.2 Sun Pharma Business Overview
  34. 4.6.3 Sun Pharma IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sun Pharma IL-23 Receptor Antagonist Product Portfolio
  36. 4.6.5 Sun Pharma Recent Developments
  37. 4.7 Sandoz
  38. 4.7.1 Sandoz Company Information
  39. 4.7.2 Sandoz Business Overview
  40. 4.7.3 Sandoz IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sandoz IL-23 Receptor Antagonist Product Portfolio
  42. 4.7.5 Sandoz Recent Developments
  43. 4.8 Samsung Bioepis
  44. 4.8.1 Samsung Bioepis Company Information
  45. 4.8.2 Samsung Bioepis Business Overview
  46. 4.8.3 Samsung Bioepis IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio
  48. 4.8.5 Samsung Bioepis Recent Developments
  49. 4.9 Janssen Pharmaceuticals
  50. 4.9.1 Janssen Pharmaceuticals Company Information
  51. 4.9.2 Janssen Pharmaceuticals Business Overview
  52. 4.9.3 Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio
  54. 4.9.5 Janssen Pharmaceuticals Recent Developments
  55. 4.10 Eli Lilly
  56. 4.10.1 Eli Lilly Company Information
  57. 4.10.2 Eli Lilly Business Overview
  58. 4.10.3 Eli Lilly IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Eli Lilly IL-23 Receptor Antagonist Product Portfolio
  60. 4.10.5 Eli Lilly Recent Developments
  61. 4.11 Celltrion
  62. 4.11.1 Celltrion Company Information
  63. 4.11.2 Celltrion Business Overview
  64. 4.11.3 Celltrion IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Celltrion IL-23 Receptor Antagonist Product Portfolio
  66. 4.11.5 Celltrion Recent Developments
  67. 4.12 Biocon Biologics
  68. 4.12.1 Biocon Biologics Company Information
  69. 4.12.2 Biocon Biologics Business Overview
  70. 4.12.3 Biocon Biologics IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Biocon Biologics IL-23 Receptor Antagonist Product Portfolio
  72. 4.12.5 Biocon Biologics Recent Developments
  73. 4.13 Amgen
  74. 4.13.1 Amgen Company Information
  75. 4.13.2 Amgen Business Overview
  76. 4.13.3 Amgen IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Amgen IL-23 Receptor Antagonist Product Portfolio
  78. 4.13.5 Amgen Recent Developments
  79. 4.14 Almirall
  80. 4.14.1 Almirall Company Information
  81. 4.14.2 Almirall Business Overview
  82. 4.14.3 Almirall IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Almirall IL-23 Receptor Antagonist Product Portfolio
  84. 4.14.5 Almirall Recent Developments
  85. 4.15 AbbVie Biotechnology
  86. 4.15.1 AbbVie Biotechnology Company Information
  87. 4.15.2 AbbVie Biotechnology Business Overview
  88. 4.15.3 AbbVie Biotechnology IL-23 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio
  90. 4.15.5 AbbVie Biotechnology Recent Developments
5 Global IL-23 Receptor Antagonist Market Scenario by Region
  1. 5.1 Global IL-23 Receptor Antagonist Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global IL-23 Receptor Antagonist Sales by Region: 2021-2032
  3. 5.2.1 Global IL-23 Receptor Antagonist Sales by Region: 2021-2026
  4. 5.2.2 Global IL-23 Receptor Antagonist Sales by Region: 2027-2032
  5. 5.3 Global IL-23 Receptor Antagonist Revenue by Region: 2021-2032
  6. 5.3.1 Global IL-23 Receptor Antagonist Revenue by Region: 2021-2026
  7. 5.3.2 Global IL-23 Receptor Antagonist Revenue by Region: 2027-2032
  8. 5.4 North America IL-23 Receptor Antagonist Market Facts & Figures by Country
  9. 5.4.1 North America IL-23 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America IL-23 Receptor Antagonist Sales by Country (2021-2032)
  11. 5.4.3 North America IL-23 Receptor Antagonist Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe IL-23 Receptor Antagonist Market Facts & Figures by Country
  16. 5.5.1 Europe IL-23 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe IL-23 Receptor Antagonist Sales by Country (2021-2032)
  18. 5.5.3 Europe IL-23 Receptor Antagonist Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific IL-23 Receptor Antagonist Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific IL-23 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific IL-23 Receptor Antagonist Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific IL-23 Receptor Antagonist Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America IL-23 Receptor Antagonist Market Facts & Figures by Country
  41. 5.7.1 South America IL-23 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America IL-23 Receptor Antagonist Sales by Country (2021-2032)
  43. 5.7.3 South America IL-23 Receptor Antagonist Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa IL-23 Receptor Antagonist Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa IL-23 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa IL-23 Receptor Antagonist Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global IL-23 Receptor Antagonist Sales by Type (2021-2032)
  2. 6.1.1 Global IL-23 Receptor Antagonist Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2032)
  4. 6.2 Global IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  5. 6.2.1 Global IL-23 Receptor Antagonist Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2032)
  7. 6.3 Global IL-23 Receptor Antagonist Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global IL-23 Receptor Antagonist Sales by Application (2021-2032)
  2. 7.1.1 Global IL-23 Receptor Antagonist Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2032)
  4. 7.2 Global IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  5. 7.2.1 Global IL-23 Receptor Antagonist Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2032)
  7. 7.3 Global IL-23 Receptor Antagonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 IL-23 Receptor Antagonist Value Chain Analysis
  2. 8.1.1 IL-23 Receptor Antagonist Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 IL-23 Receptor Antagonist Production Mode & Process
  5. 8.2 IL-23 Receptor Antagonist Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 IL-23 Receptor Antagonist Distributors
  8. 8.2.3 IL-23 Receptor Antagonist Customers
9 Global IL-23 Receptor Antagonist Analyzing Market Dynamics
  1. 9.1 IL-23 Receptor Antagonist Industry Trends
  2. 9.2 IL-23 Receptor Antagonist Industry Drivers
  3. 9.3 IL-23 Receptor Antagonist Industry Opportunities and Challenges
  4. 9.4 IL-23 Receptor Antagonist Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst